How many mg of Semax a day: dosing protocols and clinical evidence

Last updated 2026-07-24

What is the standard clinical dose of Semax?

The only body of published human dose-finding work comes from Russian clinical trials in stroke, traumatic brain injury, and optic nerve disease. In ischemic stroke, the most studied indication, doses ranged from 12,000 to 18,000 micrograms per day (12 to 18 mg) given by slow intravenous infusion over 5 to 10 days. ^[1] One 2018 Russian neurology study reported administering Semax at different stages of stroke, with intravenous doses titrated from 6,000 mcg up to 18,000 mcg daily depending on stroke severity and time from onset. ^[1] Those doses are high because they were designed for acute neuroprotection under direct medical supervision. Lower intranasal protocols (600 to 3,000 mcg daily) have been tested in smaller Russian trials for cognitive symptoms and minor vascular cognitive impairment, but these are often published in Russian-language journals and lack the sample size or replication you see in Western drug development. ^[2] It's important to recognise what this literature represents. Semax has decades of regulatory approval in Russia and is used routinely in neurology departments there. But it has never been through FDA review, never appeared in a major Western Phase III trial, and most dose-response data comes from studies that would be considered exploratory or underpowered by US standards. That doesn't make the findings false. It means the uncertainty range is wide and the replication is thin.

How much Semax do people actually use outside of clinical settings?

Western nootropic users who source Semax from research chemical suppliers or international pharmacies typically use 200 to 600 micrograms per day, split into two or three intranasal doses. That's one tenth to one twentieth of the intravenous stroke doses. Some go higher (1,000 to 1,500 mcg daily), but there is no published pharmacokinetic study describing what nasal bioavailability actually is, so these are extrapolations from anecdote and Russian package inserts. A common pattern in online discussion (for example, the subreddit r/Nootropics) is 300 mcg in the morning and 300 mcg midday, delivered via nasal spray. Users report a threshold for perceived effect somewhere around 200 to 400 mcg per dose, with effects plateauing or becoming unpleasant (headache, irritability, overstimulation) above 800 mcg per dose. None of this is controlled data. It's pooled self-report, useful as context but not as a dosing table. You'll find suppliers offering 0.1% or 1% nasal spray solutions. A 0.1% solution delivers roughly 50 mcg per spray (assuming 50 microlitre spray volume). A 1% solution delivers 500 mcg per spray. That means six sprays of 0.1% solution per day (three per nostril, twice daily) gives you 300 mcg total. Always calculate backwards from the stated concentration and confirm the volume per actuation before dosing.

What dose did the neuroprotection studies use?

The most cited neuroprotection work uses doses far above what a typical user would self-administer. A 2010 study in rats found that Semax at 50 micrograms per kilogram activated neurotrophin gene transcription after middle cerebral artery occlusion. ^[3] A 2020 transcriptomic study in rats used a single intraperitoneal dose of 600 mcg/kg and observed genome-wide expression changes in ischemic brain tissue. ^[4] A 2025 study in female mice with spinal cord injury used 500 mcg/kg and reported functional recovery linked to μ-opioid receptor deubiquitination. ^[5] Those animal doses, scaled allometrically to a 70 kg human, imply roughly 5,000 to 40,000 mcg (5 to 40 mg) depending on the conversion factor you use (FDA's typically uses a 6.2× rat-to-human multiplier for surface area scaling, but the literature is inconsistent). Russian stroke trials landed in that same range: 12,000 to 18,000 mcg per day IV. ^[1] The disconnect between those doses and the 200 to 600 mcg daily intranasal doses commonly discussed online is obvious. There is no published PK study showing nasal Semax achieves CNS concentrations comparable to IV administration. People assume it does because it's a small peptide and nasal delivery bypasses first-pass metabolism. That assumption may be correct, but it's not proven. For more on the biological mechanisms these doses are thought to engage, see our overview at Semax.

Is there a Semax dosage chart based on clinical data?

No formal dose-escalation or dose-response curve has been published in a Western peer-reviewed journal. The closest thing to a dosage chart comes from the Russian package inserts for the approved 0.1% and 1% nasal drops (brand names Semax and Semax 1%), which recommend: - 0.1% solution: 2 to 3 drops per nostril, 2 to 3 times daily (roughly 600 to 1,200 mcg total per day) for cognitive or mild vascular symptoms, 7 to 14 days.

• 1% solution: 2 to 3 drops per nostril, 1 to 2 times daily (roughly 2,000 to 6,000 mcg total per day) for acute neurological indications, under medical supervision. Those are the manufacturer's recommendations in Russia, where Semax is a registered pharmaceutical. They are not FDA guidance, they are not based on placebo-controlled trials with Western-standard endpoints, and they do not appear in the US Pharmacopeia or any comparable reference. If you see a "Semax dosage chart" on a nootropics forum or a supplement blog, check whether it cites a primary source. Most do not. The lack of a published dose-response curve is a real limitation. We don't know if 300 mcg nasal is 50% as effective as 600 mcg, or 5%, or not measurably different. We don't know whether twice-daily dosing is better than once-daily or whether tolerance develops over weeks. That uncertainty is the cost of working with a compound that has extensive clinical use in one country and almost none elsewhere.

What route of administration changes the dose requirements?

Route matters because bioavailability differs, but the published data is thin. Intranasal administration is the most common route in Russian clinical practice and in Western off-label use. A 2010 study compared intranasal, subcutaneous, and intraperitoneal administration in rats and found that all three routes produced nootropic and analgesic effects, but the onset and duration differed. ^[2] The authors stated that intranasal delivery was effective but did not report absolute bioavailability. Intravenous infusion, the route used in stroke trials, guarantees 100% bioavailability. Intranasal is thought to be lower, perhaps 10% to 50% based on peptide physicochemistry and analogy to other small peptides, but that's extrapolation, not measurement. Subcutaneous injection is mentioned occasionally in Russian case reports but is not common in Western use. There is no published comparison of plasma levels after equal doses by IV, nasal, and subcutaneous routes in humans. If you're considering Semax injection rather than nasal spray, you're in largely uncharted territory. The handful of anecdotal reports suggest subcutaneous doses of 500 to 1,000 mcg, but there's no PK to confirm whether that's equivalent to a higher or lower nasal dose. The safest assumption is that nasal and injectable are not interchangeable milligram-for-milligram.

Does the dose change depending on whether you're using Semax or N-Acetyl Semax Amidate?

N-Acetyl Semax Amidate (NA-Semax-A) is an acetylated and amidated analogue designed to resist peptidase degradation and extend half-life. The structural modifications mean it's a different molecule with different pharmacokinetics. A 2016 study found that N-terminal acetylation changes Semax's coordination with copper(II) and zinc(II), which the authors suggested could alter its interaction with amyloid-beta and its overall biological activity. ^[6] In practice, online vendors and users treat NA-Semax-A as "stronger" and recommend doses roughly half those of standard Semax: 150 to 400 mcg per day intranasal instead of 300 to 600 mcg. That practice is based on subjective reports, not on head-to-head PK studies. There is no published trial comparing equipotent doses of Semax and NA-Semax-A in humans. If you switch between them, start low and adjust based on response. For a detailed comparison, see Semax vs N-Acetyl Semax Amidate.

How long does one dose of Semax last in your system?

Nobody has published a human plasma concentration-time curve for Semax, so the elimination half-life is unknown. Peptides this size (seven amino acids, ~800 Da) typically have half-lives measured in minutes to a couple of hours if not protected from peptidases. The fact that Russian protocols call for multiple daily doses suggests the half-life is short enough that single daily dosing doesn't maintain stable levels. A 2020 functional connectomics study using resting-state fMRI in humans found that Semax altered default mode network connectivity, but the study didn't measure blood levels or track how long the effect persisted after the last dose. ^[7] A 2018 study reported that effects on brain default mode network activity were detectable during the dosing period but didn't follow patients long enough to establish a washout curve. ^[8] Without real PK data, people dose by perceived effect. A common pattern is morning and midday dosing, with users reporting that effects last 4 to 6 hours per dose. That's consistent with a half-life of 1 to 2 hours but is not a substitute for measured data. For more on duration and timing, see Semax half life.

What happens if you take too much Semax?

There is no published case series of Semax overdose. The Russian trials used very high doses (up to 18,000 mcg IV daily) without reporting serious adverse events, which suggests a wide therapeutic index. ^[1] Animal studies have used single doses up to 600 mcg/kg in rats (roughly 60 mg in a human by allometric scaling) without mortality. ^[4] Anecdotal reports of excessive dosing (1,000+ mcg nasal in a single dose) describe headache, anxiety, overstimulation, and difficulty sleeping. One 2005 study in rodents found that Semax increased dopaminergic and serotonergic turnover in the striatum, which could explain stimulant-like side effects at higher doses. ^[9] A 2023 study found that synthetic corticotropins including Semax interact with GABA receptor systems, potentially modulating anxiety and arousal. ^[10] The absence of overdose reports doesn't mean the dose ceiling is infinite. It means we lack systematic data. If you're using Semax outside a clinical setting, start at the low end of the reported range (200 to 300 mcg per dose), assess your response over several days, and increase gradually if needed. For a full safety profile, see Semax side effects.

Is Semax legal to use at these doses in the United States?

Semax is not an FDA-approved drug. It does not appear on the DEA controlled substances schedules, so it's not a scheduled drug. It is not approved for any indication under 21 U.S.C. 355, which means selling it as a drug for human use (for example, with dosing instructions or disease claims) is illegal without an NDA. ^[11] Semax also does not appear on the FDA's bulks lists (21 CFR 216.23 for 503A pharmacies, 21 CFR 216.24 for 503B outsourcing facilities), which means compounding pharmacies cannot legally compound it unless the prescriber can demonstrate it's for an individual patient under a valid prescription and the pharmacy meets specific 503A criteria. ^{[12] [13]} That's a narrow pathway, and most pharmacies won't take it. The practical result is that Semax in the US is sourced either as a "research chemical" from grey-market peptide vendors (sold with "not for human consumption" disclaimers) or from international pharmacies in countries where it's approved. Possessing it for personal use is not prosecuted, but there's no legal retail pathway. Dosing information from Russian package inserts or clinical trials is not FDA-sanctioned guidance. You're working from foreign medical literature and anecdote. That's the reality for anyone researching this compound in the US. For sourcing discussion, see Where to buy Semax: r/Nootropics.

What does a typical provider-reviewed Semax protocol look like?

Semax Labs offers a provider-reviewed nasal spray protocol, where a licensed clinician evaluates your health history and, if appropriate, writes a prescription that's fulfilled by a US compounding pharmacy partner. The typical starting dose in that model is 300 mcg per day (one spray of a 0.1% solution per nostril in the morning), used for 10 to 14 days initially, then adjusted based on subjective response and tolerability. That approach doesn't change the underlying evidence base, which is still mostly Russian and not replicated in Western RCTs. What it does change is accountability: a prescriber reviews your contraindications, a licensed pharmacy prepares the formulation under USP standards, and you have a record and a contact if something goes wrong. It's the difference between sourcing from a research chemical vendor with no chain of custody and working through a regulated compounding pathway. If you're weighing whether to self-source or use a provider-reviewed route, consider your risk tolerance and the quality of the sourcing options available. Grey-market peptide purity is variable, labelling is often inaccurate, and you have no recourse if the product is contaminated or misdosed. A compounding pharmacy isn't perfect, but it's subject to state board oversight and USP 795/797 standards.

What should you track if you're dosing Semax?

Because Semax is almost never prescribed with formal monitoring in the US, you're responsible for tracking your own response. Keep a simple daily log: dose (in micrograms), time of day, subjective effects (focus, mood, energy, side effects), and any changes in sleep or appetite. Note the batch or lot number of your product if available. If you're using it for cognitive symptoms, pick one or two objective measures: a simple working memory test (digit span, N-back), a timed task (Stroop test, trail-making), or a mood scale (PHQ-9, GAD-7). Don't rely on subjective impression alone. The placebo effect is strong with nootropics, and publication bias in the Russian literature likely inflates the reported effect sizes. If you develop persistent headache, anxiety, insomnia, or any cardiovascular symptoms (chest pain, palpitations, shortness of breath), stop and consult a physician. The safety profile in the published trials is reassuring, but those trials excluded patients with unstable cardiovascular disease, and nobody has studied long-term daily use (months to years) in healthy volunteers. You're in the territory of informed self-experimentation, not evidence-based medicine.

Frequently asked questions

How many mg of Semax should a beginner start with?

Start with 200 to 300 micrograms (0.2 to 0.3 mg) per day, split into one or two intranasal doses. Use that dose for 5 to 7 days before increasing. Most subjective effect reports describe a threshold around 200 to 400 mcg per dose, so starting lower lets you assess tolerability without overshooting.

Is 1 mg of Semax per day enough to see cognitive effects?

1,000 micrograms (1 mg) per day is at the higher end of typical nootropic dosing and above the starting range in most Russian package inserts for mild cognitive symptoms (600 to 1,200 mcg). Anecdotal reports suggest effects plateau or side effects increase above 600 to 800 mcg per day. There's no published dose-response curve to confirm where the ceiling is.

Can you take Semax once a day or does it need to be split?

Russian protocols and online practice both favour splitting the daily dose into two or three administrations. The likely reason is a short half-life (probably 1 to 2 hours, though not measured in humans). Single daily dosing is untested in controlled trials. If you prefer once-daily, expect effects to be shorter-lived.

How long should you stay on Semax at these doses?

Russian stroke protocols run 5 to 10 days at high IV doses. Lower-dose cognitive protocols in Russian literature typically run 10 to 14 days, sometimes repeated after a break. There is no published data on continuous daily use beyond a few weeks. Chronic use (months) is entirely anecdotal and unmonitored.

Does Semax dose need to be adjusted by body weight?

None of the Russian clinical trials dosed by weight; they used fixed milligram amounts. Animal studies dose by weight (mcg/kg), but those results haven't been translated into weight-based human protocols. In practice, people use the same 200 to 600 mcg range regardless of whether they weigh 60 kg or 100 kg.

What's the maximum safe dose of Semax per day?

Russian stroke trials used up to 18,000 mcg IV daily without reported serious adverse events, suggesting a high ceiling in supervised settings. For intranasal self-administration, doses above 1,500 mcg per day are rarely reported and not studied. A reasonable conservative ceiling is 1,000 mcg per day unless under medical supervision.

Is Semax more effective at higher doses?

We don't know. There's no published dose-response curve in humans for any endpoint (cognitive, mood, recovery). The Russian stroke data shows benefit at very high doses in acute settings, but that doesn't mean doubling your 300 mcg nasal dose will double the effect. Anecdotal reports suggest diminishing returns and more side effects above 600 to 800 mcg per day.

Can you use Semax every day long-term?

There is no published trial of daily Semax use extending beyond a few weeks. The longest controlled data is 10 to 14 days. Russian clinical use often involves short courses (1 to 2 weeks) repeated as needed, not continuous daily dosing. Long-term daily use is uncharted and unmonitored.

How do you measure the dose from a nasal spray bottle?

Check the stated concentration (for example, 0.1% = 1 mg/mL) and the spray volume (typically 50 to 100 microlitres per actuation). A 50 mcL spray from a 1 mg/mL solution delivers 50 mcg. Count sprays per nostril and multiply. If the bottle doesn't state volume per spray, contact the supplier or assume 50 mcL as a rough estimate.

Does Semax dose differ between nasal spray and injectable forms?

Injectable (subcutaneous) use is rarely documented. The few anecdotal reports suggest 500 to 1,000 mcg subcutaneous, but there's no PK comparison to nasal. Assume they're not equivalent milligram-for-milligram. If switching routes, start at the low end of the reported range for that route and adjust cautiously.

What dose did the neuroprotection studies in animals use?

Rat studies used 50 to 600 mcg/kg. Scaled allometrically to a 70 kg human, that implies roughly 5,000 to 40,000 mcg (5 to 40 mg), which matches the high IV doses in Russian stroke trials (12,000 to 18,000 mcg). Nasal self-dosing at 200 to 600 mcg daily is far below that range.

Should you increase Semax dose if you don't feel anything after a week?

If 300 mcg per day for 7 days produces no subjective change, you can cautiously increase to 400 to 500 mcg per day. But consider that Semax's cognitive effects may be subtle or may require objective testing to detect. Not feeling a stimulant-like "kick" doesn't mean it's not working. And if a higher dose still produces nothing, the compound may simply not suit you.

Is there a Semax dosage chart for cognitive enhancement?

No evidence-based chart exists. The only formal guidance is from Russian package inserts (600 to 1,200 mcg per day for mild cognitive symptoms). Online nootropic communities commonly use 200 to 600 mcg per day. Any "dosage chart" you find online is either copied from Russian prescribing info or is someone's opinion. Neither is FDA-reviewed.

How much Semax do Russian doctors prescribe?

In Russia, neurologists prescribe Semax at 600 to 3,000 mcg per day intranasally for mild cognitive or vascular symptoms, and 12,000 to 18,000 mcg per day IV for acute stroke or severe neurological injury. Those protocols are in the Russian formulary but not validated in Western RCTs. They represent routine clinical use, not experimental dosing.

Sources

1. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018 (PMID 29798983): Russian clinical trial reporting intravenous Semax doses of 6,000 to 18,000 mcg per day in ischemic stroke treatment at different stages.
2. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 2010 (PMID 21268834): Study of nootropic and analgesic effects of Semax following different routes of administration, including lower intranasal doses.
3. Cellular and Molecular Neurobiology, 2010 (PMID 19633950): Rat study showing Semax and Pro-Gly-Pro activate neurotrophin gene transcription after cerebral ischemia.
4. Genes, 2020 (PMID 32580520): Transcriptomic analysis in rats using intraperitoneal Semax at 600 mcg/kg following cerebral ischemia-reperfusion.
5. British Journal of Pharmacology, 2025 (PMID 40692165): Study in female mice showing Semax at 500 mcg/kg targets the μ opioid receptor gene Oprm1 to promote functional recovery after spinal cord injury.
6. Journal of Inorganic Biochemistry, 2016 (PMID 27586814): Study reporting that N-terminus acetylation of Semax alters its coordination with copper(II) and zinc(II) and changes biological properties.
7. Doklady Biological Sciences, 2020 (PMID 32342318): Functional connectomic study using resting-state fMRI to study Semax effects on brain connectivity.
8. Bulletin of Experimental Biology and Medicine, 2018 (PMID 30225715): Study reporting that Semax alters the default mode network of the brain during the dosing period.
9. Neurochemical Research, 2005 (PMID 16362768): Rodent study showing Semax activates dopaminergic and serotonergic brain systems, which may explain stimulant-like side effects at higher doses.
10. Chemical Biology & Drug Design, 2023 (PMID 36828803): Study reporting that synthetic corticotropins including Semax interact with GABA receptor systems, potentially modulating anxiety and arousal.
11. 21 U.S.C. 353a, pharmacy compounding statute: Federal statute establishing the legal framework for pharmacy compounding, under which unapproved drugs like Semax can only be compounded under specific conditions.
12. 21 CFR 216.23, 503A Bulks List: FDA regulation listing bulk drug substances that 503A compounding pharmacies may use; Semax does not appear on this list.
13. 21 CFR 216.24, 503B Bulks List: FDA regulation listing bulk drug substances that 503B outsourcing facilities may use; Semax does not appear on this list.